Shijiazhuang No. 4 Pharmaceutical Co., Ltd is a large integrated pharmaceutical enterprise integrating science and technology research and development, industrial production and marketing trade and formed a new industrial development pattern, i. e. Producing large-capacity injection as the leading product and tablets, capsules, oral solution and other dosage forms as the secondary products. There are more than ten international advanced production lines for the leading product infusion solution, its production scale, technology level, brand influence and economic benefit are on the forefront of domestic counterparts, and it has become one of China′s top 100 pharmaceutical industry enterprises and China′s top 10 chemical and pharmaceutical industry preparation export-oriented excellent enterprise brands for many consecutive years.
Shijiazhuang No. 4 Pharmaceutical Co., Ltd., as one of the leading manufacturers in Chinese pharmaceutical industry and a well-known brand, has a business history of nearly seventy years.
The production line has achieved full automation and information in the production process and logistics process and reached international advanced level by integrating the world′s leading equipment and technology. With product quality as its life, the Group always organizes production in strict accordance with GMP requirements, establishes and implements superior service concepts and measures and provides guarantee for the health of the majority of patients at home and abroad with excellent quality products and services. Driven by the brand strategy, with growing economic benefits year by year and continuously improving overall strength, it has become one of the fastest growing pharmaceutical enterprises. Its enterprise visibility and reputation are soaring, and it has won many awards such as National Quality Efficiency Type Advanced Enterprise, May 1 Labor Medal, Brand Product, AAA Grade Credit Enterprise, Business Enterprise of Observing Contract and Valuing Credit and other awards.
The company is in a new industrial development pattern now, i. e. Producing infusion solution as the leading product and tablets, capsules, injection and other forms as well as biological agents, medical kits and other materials as the secondary products. There are more than ten international advanced production lines for the leading product infusion solution, its production scale, technology level, brand influence and economic benefit are on the forefront of domestic counterparts, and it has become one of China′s top 100 pharmaceutical industry enterprises and China′s top 10 chemical and pharmaceutical industry preparation export-oriented excellent enterprise brands for many consecutive years.
The group products are radiated to all provinces, autonomous regions and municipalities in China in addition to Tibet and Taiwan and also exported to many overseas markets, including more than 80 countries such as Russia, Uzbekistan, Australia, New Zealand, Brazil, Bolivia, Costa Rica, Angola, Benin, involving in Asia, the Americas, Europe, Australia, Africa and other continents, and it has become one of the main export enterprises of infusion products. To speed up the development of foreign trade, the Group has identified the business development and cooperation plan (with APEC economy counties as the target) and strives to achieve greater leap of foreign trade.
